## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Review Proposal Project**

# NICE Technology Appraisal No.23; Temozolomide for the treatment of recurrent malignant glioma, and No.121; Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma

### Provisional matrix of consultees and commentators

Consultees		Commentators (no right to submit or appeal)		
Company		General		
•	Accord Healthcare (temozolomide)	Allied Health Professionals Federation		
•	Allergan (temozolomide)	Association of British Healthcare		
•	Eisai (carmustine implants)	Industries		
•	Merck Sharp & Dohme (temozolomide)	Board of Community Health Councils in Wales		
•	Medac (temozolomide)	British National Formulary		
•	Pfizer (temozolomide)	Care Quality Commission		
•	ProStrakan (carmustine implants)	Department of Health, Social Services		
•	Sun Pharmaceuticals UK	and Public Safety for Northern Ireland		
	(temozolomide)	EUCOMED		
•	Žentiva (temozolomide)	Healthcare Improvement Scotland		
	· · · · · ·	Medicines and Healthcare Products		
Patient/carer groups		Regulatory Agency		
•	Action for Sick Children	National Association of Primary Care		
•	Astro Brain Tumour Fund	National Pharmacy Association		
•	Black Health Agency	NHS Alliance		
•	Brain and Spine Foundation	NHS Commercial Medicines Unit		
•	Brain Tumour Action	NHS Confederation		
•	Brain Tumour Charity	Scottish Medicines Consortium		
•	Brainstrust			
•	Brain Tumour Buddies	Comparator manufacturers		
•	British Brain Tumour Association	Alliance Pharmaceuticals		
•	Cancer52	(procarbazine)		
•	Cancer Black Care	Hospira UK (vincristine)		
•	Cancer Equality	Medac (lomustine)		
•	Childhood Cancer Parents Alliance	Teva UK (vincristine)		
•	Children's Cancer and Leukaemia			
	Group	Relevant research groups		
•	Children with Cancer	Abbie's Army		
•	CLIC Sargent HAWC	Andrew McCartney Trust Fund for Brain Tumour Research		
•	Helen Rollason Cancer Charity	Astro Brain Tumour Fund		
•	Independent Cancer Patients Voice	Brain Tumour Research		
•	Katy Holmes Trust	Brain Tumour Research Campaign		
•	Lyla Nsouli Foundation	Headcase Cancer Trust		
•				

NICE Technology Appraisal No.23; Temozolomide for the treatment of recurrent malignant glioma, and No.121; Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma Issue date: December 2015 Page 1 of 3

•	Macmillan Cancer Support	•	Institute of Cancer Research
•	Maggie's Centres	•	Institute of Neurology
•	Marie Curie Cancer Care	•	MRC Clinical Trials Unit
•	Muslim Council of Britain	•	National Cancer Research Institute
•	National Children's Bureau	•	National Cancer Research Network
•	Neurological Alliance		National Institute for Health Research
•	Neurosupport		Oracle Cancer Trust
•	Ollie Young Foundation		
•	Rarer Cancers Foundation	Ass	ociated Public Health Groups
•	Ryan Ninan Children's charity		Public Health England
•	South Asian Health Foundation		Public Health Wales
•	Specialised Healthcare Alliance	·	
•	Tenovus		
•	Teenage Cancer Trust		
•	Together for Short Lives		
•	Tony Souster Glioblastoma Charity		
Pr	ofessional groups		
•	Association of Anaesthetists		
•	Association of British Neurologists		
•	Association of Cancer Physicians		
•	Association of Surgeons of Great		
	Britain and Ireland		
•	British Association of Head and Neck		
	Oncologists		
•	British Association of Head and Neck		
	Oncology Nurses		
•	British Geriatrics Society		
•	British Institute of Radiology		
•	British Psychosocial Oncology Society		
•	British Skull Base Society		
•	Cancer Research UK		
•	Royal College of Anaesthetists		
•	Royal College of General Practitioners		
•	Royal College of Nursing		
•	Royal College of Pathologists		
•	Royal College of Physicians		
•	Royal College of Radiologists		
•	Royal College of Surgeons		
•	Royal Pharmaceutical Society		
	Royal Society of Medicine		
•			
•	Society and College of Radiographers		
•	Society of British Neurological		
	Surgeons		
•	UK Clinical Pharmacy Association		
•	UK Health Forum		

• UK Oncology Nursing Society

#### <u>Others</u>

- Department of Health
- NHS Dudley CCG
- NHS England
- NHS Wandsworth CCG
- Welsh Government

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

#### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

## **Definitions:**

#### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

<sup>&</sup>lt;sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.

NICE Technology Appraisal No.23; Temozolomide for the treatment of recurrent malignant glioma, and No.121; Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma Issue date: December 2015 Page 4 of 3